Provided by Tiger Trade Technology Pte. Ltd.

Marker Therapeutics, Inc.

1.39
+0.170013.93%
Post-market: 1.37-0.0200-1.44%17:39 EDT
Volume:99.37K
Turnover:136.54K
Market Cap:23.18M
PE:-2.89
High:1.44
Open:1.25
Low:1.25
Close:1.22
52wk High:2.46
52wk Low:0.8099
Shares:16.67M
Float Shares:14.12M
Volume Ratio:1.11
T/O Rate:0.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4806
EPS(LYR):-0.7945
ROE:-76.87%
ROA:-44.14%
PB:1.91
PE(LYR):-1.75

Loading ...

Company Profile

Company Name:
Marker Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
1999
Employees:
5
Office Location:
2450 Holcombe Blvd,TMC Partners Office 1.311,Houston,Texas,United States
Zip Code:
77021
Fax:
- -
Introduction:
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Directors

Name
Position
David Eansor
Chairman and Director
Juan Vera
Chief Executive Officer and Director and President and Principal Financial Officer
Maria Bernadette Madel
Director, Corporate Operations and External Communications
Katharine Knobil
Director
Kathryn Penkus Corzo
Director
Steven Elms
Director

Shareholders

Name
Position
Juan Vera
Chief Executive Officer and Director and President and Principal Financial Officer
Maria Bernadette Madel
Director, Corporate Operations and External Communications